Wordt geladen...
New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
Ixazomib is the first oral proteasome inhibitor to be approved, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was on the basis of results from the phase 3, double-blind, placebo-controlle...
Bewaard in:
| Gepubliceerd in: | J Blood Med |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5573039/ https://ncbi.nlm.nih.gov/pubmed/28860887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S102328 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|